ORGO
Organogenesis Holdings Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-53/100
Last price
1.34
▲ 0.05 (3.88%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.24
Prev close
1.29
Day high
1.35
Day low
1.29
Volume
608.73K
Market cap
$172.42M
P/E (TTM)
—
52W range
1.28 – 7.08
Day trading desk
Gap from prior close
-3.88%
Prior close 1.29
VWAP
1.33
+0.69% from price
Relative volume
1.46×
Normal
Session range
8.87%
1.24 – 1.35
Position in range
91%
Near session high
ATR (14D)
0.07
4.86% of price
Prior day high
1.34
PDH
Prior day low
1.27
PDL
Bid / ask spread
—
Quote not published
Session volume
1.13M
Avg 773.75K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.25%
-5.2%
1M
-21.64%
-22.8%
3M
-45.75%
-50.3%
6M
-40.71%
-58.9%
YTD
-74.13%
-88.4%
1Y
-68.76%
-85.2%
3Y
-57.86%
-140.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ORGO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
57.34M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 9, 26 | LEIBOWITZ ARTHUR S Director |
BUY | 5.00K | $13.40K | Direct |
| Mar 9, 26 | DRISCOLL MICHAEL JOSEPH Director |
BUY | 10.00K | $26.69K | Direct |
| Feb 18, 26 | GILLHEENEY GARY S. SR. Chief Executive Officer |
STOCK | 1.08M | $0 | Direct |
| Feb 18, 26 | GILLHEENEY GARY S. SR. Chief Executive Officer |
STOCK | 1.08M | $0 | Direct |
| Feb 18, 26 | FREEDMAN LORI Officer |
STOCK | 245.91K | $0 | Direct |
| Feb 18, 26 | FREEDMAN LORI Officer |
STOCK | 246.34K | $0 | Direct |
| Feb 18, 26 | LEIBOWITZ ARTHUR S Director |
STOCK | 48.83K | $0 | Direct |
| Feb 18, 26 | GIACOMIN JON L Director |
STOCK | 48.83K | $0 | Direct |
| Feb 18, 26 | BILBO PATRICK Chief Operating Officer |
STOCK | 259.55K | $0 | Direct |
| Feb 18, 26 | BILBO PATRICK Chief Operating Officer |
STOCK | 260.04K | $0 | Direct |
| Feb 18, 26 | GROW BRIAN Officer |
STOCK | 282.70K | $0 | Direct |
| Feb 18, 26 | GROW BRIAN Officer |
STOCK | 283.19K | $0 | Direct |
| Feb 18, 26 | MONTECALVO ANTONIO S Officer |
STOCK | 51.84K | $0 | Direct |
| Feb 18, 26 | MONTECALVO ANTONIO S Officer |
STOCK | 51.95K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADES ALAN A |
Director and Beneficial Owner of more than 10% of a Class of Security | 102.17M | Stock Gift |
BILBO PATRICK |
Chief Operating Officer | 1.13M | Stock Award(Grant) |
CAVORSI ROBERT |
Officer | 276.22K | Stock Award(Grant) |
DURAIBABU PRATHYUSHA |
Director | 247.05K | Stock Award(Grant) |
FRANCISCO DAVID |
Chief Financial Officer | 731.02K | Stock Award(Grant) |
FREEDMAN LORI |
Officer | 1.02M | Stock Award(Grant) |
GILLHEENEY GARY S. SR. |
Chief Executive Officer | 4.23M | Stock Award(Grant) |
GROW BRIAN |
Officer | 899.36K | Stock Award(Grant) |
LEIBOWITZ ARTHUR S |
Director | 291.01K | Purchase |
NUSSDORF GLENN H |
Director | 11.75M | Sale |
Fundamentals
Market cap$172.42M
Enterprise value$333.14M
Revenue (TTM)$457.45M
Gross profit$327.02M
EBITDA$-9.70M
Net income$-101.68M
EPS (TTM)$-0.83
Free cash flow$28.45M
Total cash$46.10M
Total debt$66.95M
Book value / share$1.15
Shares outstanding128.67M
Float61.06M
Short % of float17.26%
Dividend yield0.00%
Beta (5Y)1.27
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.32
PEG ratio—
Price / sales—
Price / book1.16
EV / revenue0.73
EV / EBITDA-34.34
Gross margin71.49%
Operating margin-119.25%
Profit margin-18.40%
Return on equity-25.92%
Return on assets-4.11%
Debt / equity23.24
Current ratio3.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $563.03M | $482.04M | $433.14M | $450.89M | +16.8% |
| Operating revenue | $563.03M | $482.04M | $433.14M | $450.89M | +16.8% |
| Cost of revenue | $137.52M | $115.74M | $106.48M | $105.02M | +18.8% |
| Gross profit | $425.51M | $366.30M | $326.66M | $345.87M | +16.2% |
| Research & development | $44.54M | $50.27M | $44.38M | $39.76M | -11.4% |
| Selling, general & admin | $326.24M | $294.51M | $269.75M | $283.81M | +10.8% |
| Total operating expense | $369.64M | $344.78M | $314.13M | $323.57M | +7.2% |
| Operating income | $55.87M | $21.52M | $12.53M | $22.30M | +159.6% |
| Net interest income | $2.28M | -$1.54M | -$2.19M | -$2.01M | +247.7% |
| Pre-tax income | $46.97M | -$2.81M | $10.39M | $20.28M | +1,773.3% |
| Tax provision | $9.94M | -$3.67M | $5.45M | $4.75M | +370.9% |
| Net income | $37.03M | $861.00K | $4.95M | $15.53M | +4,201.0% |
| Net income to common | $20.02M | -$937.00K | $4.95M | $15.53M | +2,236.8% |
| Basic EPS | 0.16 | -0.01 | 0.04 | 0.12 | +1,700.0% |
| Diluted EPS | 0.15 | -0.01 | 0.04 | 0.12 | +1,600.0% |
| EBIT | $55.87M | -$1.26M | $12.58M | $22.29M | +4,523.5% |
| EBITDA | $82.81M | $24.11M | $36.03M | $40.32M | +243.4% |
| Basic shares | 126.74M | 131.67M | 131.23M | 130.07M | -3.7% |
| Diluted shares | 130.25M | 131.67M | 132.75M | 132.38M | -1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.68M | $135.57M | $103.84M | $102.48M | — | -30.9% |
| Cash & short-term investments | $93.68M | $135.57M | $103.84M | $102.48M | — | -30.9% |
| Accounts receivable | $217.45M | $109.86M | $82.00M | $89.45M | — | +97.9% |
| Inventory | $29.63M | $26.22M | $28.25M | $24.78M | — | +13.0% |
| Total current assets | $362.19M | $285.94M | $225.04M | $222.61M | — | +26.7% |
| Property, plant & equipment | $159.46M | $126.24M | $156.35M | $145.66M | — | +26.3% |
| Goodwill & intangibles | $37.92M | $41.24M | $44.64M | $49.56M | — | -8.1% |
| Total assets | $598.73M | $497.89M | $460.02M | $449.36M | — | +20.3% |
| Total current liabilities | $100.12M | $77.48M | $80.51M | $75.02M | — | +29.2% |
| Current debt | — | — | $5.49M | $4.54M | $2.66M | — |
| Long-term debt | — | — | $60.74M | $66.23M | $70.77M | — |
| Total debt | $82.14M | $43.31M | $119.35M | $123.79M | — | +89.6% |
| Total liabilities | $164.81M | $112.57M | $181.36M | $183.69M | — | +46.4% |
| Retained earnings | -$3.08M | -$40.11M | -$40.97M | -$45.30M | — | +92.3% |
| Shareholder equity | $433.92M | $385.32M | $278.66M | $265.67M | — | +12.6% |
| Working capital | $262.06M | $208.46M | $144.53M | $147.59M | — | +25.7% |
| Net tangible assets | $396.00M | $344.08M | $234.02M | $216.11M | — | +15.1% |
| Shares issued | 127.68M | 126.46M | 132.04M | 131.65M | — | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $37.03M | $861.00K | $4.95M | $15.53M | +4,201.0% |
| Depreciation & amortisation | $26.94M | $25.37M | $23.45M | $18.03M | +6.2% |
| Stock-based compensation | $13.30M | $10.58M | $9.00M | $6.55M | +25.7% |
| Change in working capital | -$132.38M | -$48.89M | -$18.07M | -$34.08M | -170.8% |
| Operating cash flow | -$10.31M | $14.21M | $30.92M | $24.86M | -172.6% |
| Capital expenditure | -$14.15M | -$10.03M | -$24.36M | -$33.90M | -41.1% |
| Investing cash flow | -$14.15M | -$10.03M | -$24.36M | -$33.90M | -41.1% |
| Share buybacks | $0 | -$25.48M | $0 | $0 | +100.0% |
| Financing cash flow | -$17.36M | $27.64M | -$5.50M | -$2.20M | -162.8% |
| Free cash flow | -$24.46M | $4.18M | $6.55M | -$9.04M | -685.7% |
| End cash position | $94.33M | $136.15M | $104.34M | $103.29M | -30.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $42.80M | $36.25M | $225.07M | $150.49M | $100.78M | +18.1% |
| Operating revenue | $42.80M | $36.25M | $225.07M | $150.49M | $100.78M | +18.1% |
| Cost of revenue | $23.67M | $25.77M | $49.92M | $36.25M | $27.63M | -8.1% |
| Gross profit | $19.13M | $10.48M | $175.15M | $114.24M | $73.15M | +82.6% |
| Research & development | $18.30M | $15.16M | $10.29M | $13.22M | $10.39M | +20.7% |
| Selling, general & admin | $53.97M | $65.19M | $100.17M | $79.74M | $73.81M | -17.2% |
| Total operating expense | $71.31M | $79.37M | $109.92M | $92.59M | $83.98M | -10.2% |
| Operating income | -$52.18M | -$68.89M | $65.23M | $21.65M | -$10.83M | +24.3% |
| Net interest income | $138.00K | $380.00K | $236.00K | $415.00K | $669.00K | -63.7% |
| Pre-tax income | -$50.88M | -$68.47M | $63.43M | $21.16M | -$11.83M | +25.7% |
| Tax provision | $45.39M | -$15.32M | $19.73M | -$407.00K | -$2.44M | +396.3% |
| Net income | -$96.27M | -$53.16M | $43.70M | $21.57M | -$9.39M | -81.1% |
| Net income to common | -$99.34M | -$56.16M | $35.12M | $14.53M | -$12.20M | -76.9% |
| Basic EPS | -0.77 | -0.44 | 0.25 | 0.11 | -0.10 | -75.0% |
| Diluted EPS | -0.77 | -0.44 | 0.24 | 0.11 | -0.10 | -75.0% |
| EBIT | -$52.18M | -$68.89M | $65.23M | $21.65M | -$10.83M | +24.3% |
| EBITDA | -$45.59M | -$56.52M | $72.24M | $28.64M | -$4.17M | +19.3% |
| Basic shares | 128.67M | 127.80M | 126.91M | 126.88M | 126.85M | +0.7% |
| Diluted shares | 128.67M | 127.80M | 132.21M | 130.85M | 126.85M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.10M | $91.38M | $93.68M | $63.74M | $73.08M | -49.6% |
| Cash & short-term investments | $46.10M | $91.38M | $93.68M | $63.74M | $73.08M | -49.6% |
| Accounts receivable | $100.94M | $116.91M | $217.45M | $168.78M | $120.38M | -13.7% |
| Inventory | $29.28M | $28.43M | $29.63M | $39.58M | $33.04M | +3.0% |
| Total current assets | $200.30M | $268.50M | $362.19M | $299.75M | $260.22M | -25.4% |
| Property, plant & equipment | $151.44M | $157.82M | $159.46M | $111.36M | $110.86M | -4.0% |
| Goodwill & intangibles | $31.78M | $32.21M | $37.92M | $38.72M | $39.56M | -1.3% |
| Total assets | $406.45M | $519.99M | $598.73M | $509.83M | $461.13M | -21.8% |
| Total current liabilities | $56.96M | $76.02M | $100.12M | $90.32M | $65.84M | -25.1% |
| Total debt | $66.95M | $70.86M | $82.14M | $40.81M | $40.82M | -5.5% |
| Total liabilities | $118.31M | $138.65M | $164.81M | $123.85M | $99.91M | -14.7% |
| Retained earnings | -$152.50M | -$56.23M | -$3.08M | -$46.78M | -$68.34M | -171.2% |
| Shareholder equity | $288.13M | $381.35M | $433.92M | $385.98M | $361.22M | -24.4% |
| Working capital | $143.34M | $192.48M | $262.06M | $209.43M | $194.38M | -25.5% |
| Net tangible assets | $256.36M | $349.14M | $396.00M | $347.26M | $321.66M | -26.6% |
| Shares issued | 128.67M | 129.40M | 127.68M | 127.64M | 127.58M | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$96.27M | -$53.16M | $43.70M | $21.57M | -$9.39M | -81.1% |
| Depreciation & amortisation | $6.59M | $12.37M | $7.01M | $6.99M | $6.66M | -46.8% |
| Stock-based compensation | $3.05M | $3.64M | $4.32M | $3.06M | $2.54M | -16.1% |
| Change in working capital | $8.09M | $70.53M | -$43.67M | -$29.88M | -$38.12M | -88.5% |
| Operating cash flow | -$31.65M | $21.13M | $39.42M | $3.08M | -$32.87M | -249.8% |
| Capital expenditure | -$1.10M | -$3.15M | -$4.65M | -$2.23M | -$3.64M | +65.0% |
| Investing cash flow | -$1.10M | -$3.15M | -$4.65M | -$2.23M | -$3.64M | +65.0% |
| Financing cash flow | -$12.50M | -$20.21M | -$4.81M | -$10.21M | -$288.00K | +38.1% |
| Free cash flow | -$32.75M | $17.98M | $34.77M | $844.00K | -$36.51M | -282.2% |
| End cash position | $46.84M | $92.10M | $94.33M | $64.37M | $73.73M | -49.1% |
Options analytics
Put / call volume
0.56
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+86.6% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
25
Contracts, this expiry
Put volume
14
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.35 | -0.69 | -97.7% |
| Mar 2026 | -0.29 | -0.34 | -18.0% |
| Dec 2025 | 0.21 | 0.40 | +90.5% |
| Sep 2025 | 0.07 | 0.18 | +153.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.17 | 1 | $52.11M | -65.5% |
| Next quarter | -0.14 | 2 | $63.01M | -72.1% |
| Current year | -1.38 | 2 | $196.06M | -65.3% |
| Next year | -0.31 | 2 | $269.69M | +37.6% |
Analyst targets & ownership
Mean target$2.00
High target$2.00
Low target$2.00
Implied upside49.25%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 0
Hold2
Sell / Strong sell0 / 0
Held by insiders44.56%
Held by institutions51.68%
Institutions holding181
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.38
-2.72% from price
SMA 20
1.42
-5.55% from price
SMA 50
1.73
-22.43% from price
SMA 100
2.10
-36.13% from price
SMA 200
2.72
-50.68% from price
EMA 12
1.38
-3.24% from price
EMA 26
1.49
-10.32% from price
EMA 50
1.69
-20.84% from price
RSI (14)
35.3
Neutral
MACD (12,26,9)
-0.11
Hist 0.01
ATR (14)
0.07
4.86% of price
Realised vol 30D
48.3%
Annualised
Bollinger upper
1.56
20, 2σ
Bollinger lower
1.28
20, 2σ
50 / 200 cross
Death
1.73 vs 2.72
Trend bias
Below 200
-50.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.17
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
48.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.3%
Peak to trough
Max drawdown 5Y
-89.7%
Peak to trough
ATR 14
0.07
4.86% of price
Beta (reported)
1.27
5Y monthly, from filing
Short interest
Shares short
14.12M
Prior 14.23M
Change vs prior
-0.8%
Shorts covering
% of float
17.26%
Elevated
% of shares out
10.97%
Against total outstanding
Days to cover
21.0
Crowded exit
Float
61.06M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| May 28, 26 | Truist Securities | INITIATED | — | Hold |
| Mar 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Feb 27, 26 | BTIG | MAINTAINED | Buy | Buy |
| Dec 26, 25 | BTIG | MAINTAINED | Buy | Buy |
| Dec 15, 25 | BTIG | MAINTAINED | Buy | Buy |
| Nov 20, 25 | BTIG | MAINTAINED | Buy | Buy |
| Sep 26, 25 | BTIG | MAINTAINED | Buy | Buy |
| Aug 8, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 15, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Mar 5, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jun 28, 24 | Lake Street | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-16
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2026-02-23
Corporate Changes & Voting Matters
8-K · 2025-12-29
Periodic Financial Reports
10-Q · 2025-11-06
Headlines
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
Simply Wall St. · 58d ago
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?
Simply Wall St. · 60d ago
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
Moby · 61d ago
Organogenesis Q2 Earnings Call Highlights
MarketBeat · 61d ago
Organogenesis: Q2 Earnings Snapshot
Associated Press · 61d ago
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
GlobeNewswire · 61d ago
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
GlobeNewswire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.